And its wholly owned subsidiary, Marvel Biotechnology Inc., announces it has initiated the 4-week good laboratory practice FDA investigational new drug enabling dose-ranging rat studies for its lead drug candidate MB-204."This rat study, along with the GLP study on dogs, are the last two key studies we need to complete before entering phase 1 human clinical testing of our lead asset - MB-204," said Dr. Mark Williams, Chief Science Officer of Marvel Biosciences. "We are also in the final preparation stage of initiating the 4-week dose-ranging GLP studies on dogs and will update our shareholders on our progress." MB-204 is a novel solution to Alzheimer's that has similar properties to the Food and Drug Administration-approved drug, Istradefylline. MB-204 has, through the Company's studies, proven to be more effective and longer lasting than Istradefylline in pre-clinical studies. MB-204 is a fluorinated derivative of the U.S. FDA-approved adenosine A2a receptor antagonist, Istradefylline. Both Istradefylline and MB-204 are highly active derivatives of caffeine, the most widely consumed psychoactive drug in the world. Caffeine consumption has been associated with a reduced risk of developing Parkinson's disease, and Alzheimer's disease and improved concentration. Marvel Biosciences Corp shares V.MRVL are trading up one cent at $0.10.